Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 16:16:110.
doi: 10.1186/s12885-016-2158-8.

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

L G E M Razenberg  1   2 , Y R B M van Gestel  3 , I H J T de Hingh  4 , O J L Loosveld  5 , G Vreugdenhil  6 , L V Beerepoot  7 , G J Creemers  8 , V E P P Lemmens  9   10
Affiliations

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

L G E M Razenberg et al. BMC Cancer. .

Abstract

Background: Although the efficacy of bevacizumab has been established in patients with metastatic colorectal cancer (mCRC), population-based studies are needed to gain insight into the actual implementation of bevacizumab in daily practice. Since these studies are lacking for patients with metachronous metastases, the aim of this study is to evaluate the current role of bevacizumab in the treatment of metachronous metastases of CRC.

Methods: Data on the use of bevacizumab as palliative treatment of metachronous metastases were collected for patients diagnosed with M0 CRC between 2003 and 2008 in the Eindhoven Cancer Registry (n = 361). Median follow up was 5.3 years.

Results: One hundred eighty-five patients received bevacizumab in addition to first-line palliative chemotherapy (51%), ranging from 36% to 80% between hospitals of diagnosis (p < 0.0001). Combined cytostatic regimens (CAPOX/FOLFOX in 97%) were prescribed in the majority of patients (63%) and were associated with a higher odds for additional treatment with bevacizumab than single-agent cytostatic regimens (OR 9.9, 95% CI 5.51-18.00). Median overall survival (OS) rates were 21.6 and 13.9 months with and without the addition of bevacizumab to palliative systemic treatment respectively (p < 0.0001). The addition of bevacizumab to palliative chemotherapy was associated with a reduced hazard ratio for death (HR 0.6, 95% CI 0.45-0.73) after adjustment for patient- and tumor characteristics and the prescribed chemotherapeutic regimen.

Conclusion: Bevacizumab is adopted as a therapeutic option for metachronous metastasized CRC mainly in addition to first-line oxaliplatin-based regimens, and was associated with a reduced risk of death. The presence of inter-hospital differences in the prescription of bevacizumab reflected important differences in attitude and policies in clinical practice. Ongoing efforts should be made to further define the position of targeted agents in the treatment of metastatic colorectal cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
An overview on the palliative systemic treatment of metachronous metastases for patients diagnosed between 2003 and 2008 with stage I-III colorectal cancer in the south of the Netherlands
Fig. 2
Fig. 2
Proportion of patients receiving first-line palliative chemotherapy plus bevacizumab according to hospital of diagnosis (n = 361)
Fig. 3
Fig. 3
Overall survival according to the addition of bevacizumab to first-line systemic therapy (n = 361)
See this image and copyright information in PMC

References

    1. Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival. Acta Oncol. 2010;49(6):784–96. doi: 10.3109/02841861003733713. - DOI - PubMed
    1. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol. 2008;19(9):1600–4. doi: 10.1093/annonc/mdn176. - DOI - PubMed
    1. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, Verhoef C. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14(1):56–61. doi: 10.1111/j.1463-1318.2010.02539.x. - DOI - PubMed
    1. McArdle C. ABC of colorectal cancer: effectiveness of follow up. BMJ. 2000;321(7272):1332–5. doi: 10.1136/bmj.321.7272.1332. - DOI - PMC - PubMed
    1. BOM C. Raltitraxed, oxaliplatin en irinotecan door commissie BOM beoordeeld. Medische Oncologie. 2001;1:30–3.

Publication types